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Available online 22 October 2014Abstract Vascularization is critical for 3D tissue engineered constructs. In large size implants the ingrowth of vessels often
fails. The purpose of this study was to identify an easily accessible, clinically relevant cell source able to promote
neovascularization in engineered implants in vivo and to establish an autologous culture method for these cells.
MSCs (mesenchymal stem cells) and an endothelial progenitor containing cell (EPCC) population were obtained from human
bone marrow aspirates. The expression of endothelial-markers, uptake of acetylated low density lipoprotein (acLDL) and
tube-like structure formation capability of EPCCs were analyzed after expansion in endothelial growth medium or medium
supplemented with autologous platelet lysate (PL). EPCCs were co-seeded with MSCs on hydroxyapatite-containing
polyurethane scaffolds and then implanted subcutaneously in nude mice.
Human EPCCs displayed typical characteristics of endothelial cells including uptake of acLDL and formation of tube-like structures on
Matrigel™. In vivo, EPCCs cultured with PL triggered neovascularization. MSC/EPCC interactions promoted the maturation of newly
formed luminal structures, which were detected deep within the scaffold and partly perfused, demonstrating a connection with the
host vascular system.
We demonstrate that this population of cells, isolated in a clinically relevant manner and cultured with autologous growth factors
readily promoted neovascularization in tissue engineered constructs in vivo enabling a potential translation into the clinic.
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Vascularization is essential in tissue engineering approaches.
This is evident by the limited diffusion distance of oxygen from
blood vessels into surrounding tissue, which ranges between
150 and 200 μm (Folkman and Hochberg, 1973). Auger et al.
reported that a tissue engineered construct exceeding a size of
400 μm in any dimension has to be vascularized in order to
guarantee a sufficient supply of oxygen and nutrients to cells as
well as the clearance of metabolic products (Auger et al.,
2013). Vascularization is of particular importance for the
engineering of highly vascularized tissues, such as bone
(Laroche, 2002). It has been shown that angiogenesis is crucial
to enable bone repair (Carano and Filvaroff, 2003; Das and
Botchwey, 2011) as well as in bone tissue engineering of
constructs of clinically relevant size (Griffith and Naughton,
2002). Indications for the clinical use of tissue engineered
constructs are given in cases of critical size defects and
non-unions (Fayaz et al., 2011).
Previous studies have shown that the ingrowth of vessels
into grafts is not rapid enough to ensure cell survival (Auger et
al., 2013; Laschke et al., 2006), where re-population of
scaffolds with host endothelial cells (ECs) may take up to
14 days (Tremblay et al., 2005). In contrast, inosculation of
pre-formed tubular structures or micro-vessels could be
observed within 2–4 days (Tremblay et al., 2005; Laschke et
al., 2009). Consequently, many recent tissue engineering
approaches have focused on the in vitro pre-vascularization
of grafts by the addition of ECs (Rouwkema et al., 2006; Fuchs
et al., 2009; Henrich et al., 2009; Pang et al., 2013; Yu et al.,
2008; Duttenhoefer et al., 2013). Various cell types have been
used as source of ECs. Mature ECs such as human umbilical
vein endothelial cells (HUVECs) or human dermal microvas-
cular ECs promoted vascularization of tissue engineered
constructs in animal models (Koob et al., 2011; Thein-Han
and Xu, 2013). However, the availability and proliferation
capacity of these cells are limited and extensive and
time-consuming in vitro amplification is required (Auger et
al., 2013). Adipose tissue stromal microvascular fractions
have also been shown to be a source of ECs (Planat-Benard et
al., 2004; Scherberich et al., 2007). Other tissue engineering
approaches focus on endothelial progenitor cells (EPCs).
Asahara et al. were the first to isolate EPCs from peripheral
blood mononuclear cells (Asahara et al., 1997). EPCs originate
from the hematopoietic lineage (Masuda and Asahara, 2003)
and have significantly higher long-term proliferation capabil-
ities than mature ECs (Lin et al., 2000). Circulating EPCs
(CEPCs) are mobilized from the bone marrow (BM) niche
(Asahara et al., 1999). Two subtypes of CEPCs have been
described and termed early and late outgrowth ECs according
to the appearance of colonies after seeding mononuclear cells
on fibronectin coated plates (Lin et al., 2000; Kalka et al.,
2000). Besides, various approaches have been focused on the
direct selection of the hematopoietic progenitors by FACS or
MACS and subsequent differentiation of cells towards an EC
phenotype by supplementation of angiogenic growth factors.
These isolation and enrichment strategies have mostly
focused on the surface markers CD34, CD133 and vascular
endothelial growth factor receptor 2 (VEGFR2, also KDR or
CD309) (Masuda and Asahara, 2003; Yin et al., 1997; Peichev
et al., 2000). However, the phenotypic characterization of
EPCs remains difficult and is dependent upon species, cellsource and in vitro culture conditions (Timmermans et al.,
2009; Critser et al., 2011). EPCs are typically characterized by
their ability to bind lectin from Ulex europaeus and to take up
acetylated low density lipoproteins (acLDL) (Rafii et al.,
1994). None of these widely used criteria are specific to ECs,
and do not allow them to be distinguished from hematopoi-
etic cells, which has led to a debate about the true nature of
the various hematopoietic cell populations referred to as EPCs
(Timmermans et al., 2009; Yoder et al., 2007; Mund et al.,
2012). In contrast to the unclear identity of those cells their
angiogenic potential has been readily shown in various
preclinical and clinical studies (Krenning et al., 2009).
The expansion and maturation of mature ECs and EPCs
requires the addition of pro-angiogenic growth factors such as
VEGF. With regards the translation of cell-based therapies
into clinic, it is of interest to avoid the expensive and
controversial use of recombinant growth factors. The supple-
mentation of growth medium with platelet lysate (PL)
containing autologous growth factors represents a promising
alternative. PL has already been used to supplement cultures
of MSCs (Verrier et al., 2010). Recent work from our group has
shown that EPCs can be expanded with PL (Lippross et al.,
2011). Furthermore, EPCs grown in PL-containing medium
induced tube-formation in 3D co-cultures with MSCs after
1 week of in vitro culture (Duttenhoefer et al., 2013).
The current study aimed to enrich a human endothelial
progenitor containing cell (EPCC) population and to investi-
gate (i) its potential to differentiate towards mature ECs and
(ii) to promote neovascularization in vivo. The emphasis was
to establish an autologous culture method using PL to
facilitate the translation into clinic.
Material and methods
Preparation and characterization of platelet lysate
(PL) and platelet rich plasma (PRP)
PL was produced as previously described (Lippross et al.,
2011). In brief, platelet concentrates (5× above physiolog-
ical concentration) were obtained by platelet aphaeresis
(Kantonspital Graubünden). After centrifugation, the pellet
was resuspended in half of the original volume using
phosphate buffered saline (PBS, Sigma). PL was washed
with PBS and activated by sonication for 15 min followed by
freezing at −20 °C. Prior to use, PL was thawed and
centrifuged to eliminate remaining platelet debris, subse-
quently the supernatant was used. PRP was also prepared
from platelet concentrates. After centrifugation at 2000g
for 20 min the pellet was resuspended in the supernatant
(1/10 original volume), resulting in a final 50× enrichment
of platelets compared to the physiological density. The
PRP was activated by sonication for 15 min and freezing at
−20 °C. PL and PRP samples (n = 3) were pooled from three
different platelet concentrates and randomly matched to
normalize any donor specific influences.
The presence of angiogenic growth factors in PL (pooled
samples, n = 3) was examined using a human angiogenesis
protein array (C-series1000, RayBio). PL (1 ml/membrane)
was incubated for 60 min with the array membranes. Signal
detection was performed according to the manufacturer's
protocol. Chemiluminescence was detected after 25 min of
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Semi-quantification was performed by averaging values from
duplicated spots and measuring pixel intensity using ImageJ
(Rasband, NIH). Data are presented as relative abundance in
comparison to positive control on the membranes.
BM derived mononuclear cell (MNC) isolation and
MSC culture
BM aspirates in citrate phosphate dextrose adenine-
containing S-monovettes (Sarstedt) were obtained from
iliac crest or vertebra of patients (Suppl. Table 1) undergo-
ing routine orthopedic surgery after informed consent and
approval by the local ethic committees (KEK Bern 126/03).
BM aspirates were diluted 1:4 with PBS and layered onto
Ficoll (Histopaque-1077, Sigma) and centrifuged at 800g for
20 min at room temperature. The MNC interphase was
collected, washed with αMEM (Gibco) containing PenStrep
(100 U/ml, Gibco), 10% fetal bovine serum (FBS, Gibco)
followed by 15 min centrifugation at 400g. MNCs were seeded
at the density of 5 × 104 cells per cm2 with αMEM containing
10% FBS, PenStrep (100 U/ml) and 5 ng/ml bFGF (R&D
Systems). After 4 days, non-adherent cells were removed
and monolayer selected MSCs expanded with medium changes
every 3 days. When 80% confluency was reached cells were
detached using 0.5% trypsin-EDTA (Gibco) and reseeded at a
density of 3 × 103 cells/cm2. All experiments were performed
with cells between passages 2 and 3.
EPCC enrichment and culture
Freshly isolated MNCs were centrifuged at 300g for 10 min
and resuspended in PBS with 0.5% bovine serum albumin
(Sigma) and 2 mM EDTA (Sigma). Cells were enriched using
the MiniMACS Magnetic Microbead System (Miltenyi Biotec)
sequentially using CD34 and CD133 specific antibodies
according to the manufacturer's instructions, the obtained
cell population is referred to as an endothelial progenitor
containing cell population (EPCC). EPCCs were seeded at a
density of 5 × 104cells/cm2 in six-well plates and cultured in
either EBM-2 medium (Lonza) with full growth factor
supplementation supplied by the EGM-2 kit (Lonza), referred
to as EGM, or Iscove's Modified Dulbecco's Medium (IMDM,
Gibco) containing FBS (Gibco), PenStrep (100 U/ml), 1%
NEAA (Gibco) and PL. A combination of 2% FBS–8% PL or 5%
FBS–5% PL was used. The first medium change was
performed after 4 days, with subsequent medium changes
every 3 days. Cells were subcultured upon 80% confluency
and after trypsinization reseeded at a density of 5 × 103
cells/cm2. HUVECs (Gibco) were grown on plates coated
with Quick Coating (AngioProteomic) in EGM.
Characterization of EPCCs
Cells were analyzed for expression of endothelial marker by
flow cytometry. For immunolabeling 1–2 × 105 cells were
stained with the following antibodies alone or in different
combinations: CD34-FITC, CD34-PE, CD133-APC, CD309-PE
(Miltenyi Biotech), CD31-AlexaFluor680 (BD Bioscience) and
goat anti mouse IgG isotype control-APC (BD Bioscience) and
incubated for 30 min on ice according to the manufacturer'srecommendations. Cells were washed in PBS before analysis
using a BD FACS Aria III (BD Bioscience). At least 25,000
events were recorded per sample and a gating strategy used
to exclude cell doublets.
To analyze the uptake of acLDL, 5 × 105 cells were
seeded in six-well culture plates and left overnight. Cells
were then incubated with 1 μg/ml Dil-labeled acLDL (Life
Technologies) for 4 h at 37 °C. Subsequently, cells were
washed 3× with PBS, detached and cell-associated fluores-
cence measured by flow cytometry.
To study the ability of cells to form tube-like structures,
we seeded 3 × 104 cells in two-well Nunc Lab-Tek™ Chamber
Slides (Thermo Scientific) coated with a thin layer of
Matrigel™ (growth factor reduced, BD Bioscience) and
incubated in the same media that the cells had previously
been cultured in. Formation of tube-like structures was
observed using a Axiovert40 CFL microscope (Zeiss) 0.5 h,
6 h and 24 h after seeding and incubation at 37 °C. For
quantitative analysis images from three fields of view were
taken from each well at 5× magnification and total tube
length measured using Axiovision software (Zeiss).In vivo model of neovascularization in tissue
engineered constructs
The in vivo study was approved by the ethical committee of the
canton of Grisons in Switzerland. All procedures were per-
formed in an AAALAC approved facility and according to Swiss
animal protection law and regulations. Bioresorbable elasto-
meric polyurethane scaffolds (diameter 8 mm, thickness 2 mm)
containing nanoparticles of hydroxyapatite (PU-HA), porosity
200–600 μm were cut in half (half-moon scaffolds). Before
cell-seeding, scaffolds were incubated in IMDM medium and
degassed for 1 h. 1.5 × 106 MSCs and/or EPCCs (expanded in
IMDMwith 5% FBS–5% PL) were resuspended in 50 μl PRP, mixed
with 8 μl of a thrombin solution (50U/ml, Baxter) and
immediately seeded into the scaffolds. The following combina-
tions of cells were used: 100% MSC, 100% EPCC, 75% EPCC + 25%
MSC, 50% EPCC + 50% MSC (n = 5). Control scaffolds were
seeded with PRP alone or left untreated (n = 2). Scaffolds
were either pre-cultured for 1 week in IMDM supplementedwith
7.5% FBS, 2.5% PL, PenStrep (100 U/ml), 1% NEAA, 5 mM
β-glycerophosphate, 50 μM ascorbic acid, 10−8 M dexametha-
sone and aprotinin (500 U/ml, Sigma) or used directly
for implantation in 9-week-old female specific pathogen
free CD1-nude mice (Charles River). Two scaffolds were
implanted subcutaneously in each mouse. Mice were
anaesthetized by exposure to isoflurane. Buprenorphine
(0.1 mg/kg) was administered subcutaneously before the start
of the surgery. After preparation of the surgical area for aseptic
surgical intervention, two separate 1 cm skin incisions were
made in the dorsal midline over the thoracic spine. At each
incision, a pocket was prepared by blunt subcutaneous
preparation to one side of the thorax. One scaffold was then
placed into each pocket and the surgical incision was closed
with 5–0 Vicryl rapid (Ethicon). Following surgery, acetamino-
phen was added to the drinking water for 3 days (200 mg/
100 ml; UPSAMEDICA GmbH). Mice were housed in individually
ventilated cages within a barrier throughout the study and fed
ad libitum (“Alleinfuttermittel für Mäuse,” Art. 3436; Kliba)
with free access to drinking water. After 8 weeks themicewere
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and fixed in 70% methanol. To evaluate anastomosis of the
implants two mice per group received an intravenous injection
of 20 mg/kg FITC-labeled lectin from U. europaeus (Sigma) 1 h
prior to euthanasia.
Immunohistochemistry
Fixed scaffolds were cut in half. One half was incubated in 1%
sucrose in PBS overnight, frozen in tissue freezing medium
(Leica) and 10 μm thick cryosections were prepared. For
immunohistochemistry sections were rehydrated for 10 min in
deionizedwater, blocked for 60 minwith 5% goat serum (Vector
Laboratories) and incubated for 60 min with rabbit-anti human
α smooth muscle actin (αSMA) antibody (Abcam). After washing
sections were incubated for 30 min with TRITC-labeled
goat-anti-rabbit secondary antibody (Abcam). Sections were
washed and mounted using Prolong Gold Antifade reagent
containing DAPI (Life Technologies). Microscopic analysis was
performed using an Axiovert 200mmicroscope equippedwith an
AxiocamHRc and Axiovision software (Zeiss). A montage of the
entire cross section of the scaffold was assembled from
individual images at 10× magnification using the Mosaix tool.
Regions of interest (ROIs) were defined as (i) the whole
cross-section area (16 mm2) and (ii) the center of the scaffold
(8.6 mm2). Cell content within the ROIs was estimated by
determination of the DAPI covered area. Calculations were
made using KS software (Zeiss) and a custom made Macro in
Excel (Microsoft). The number of αSMA positive vessels was
counted manually and their penetration depth measured using
Axiovision software. Total vessel number was normalized to the
size of the section of the scaffold to account for slight
differences in scaffold size.
The second half of each scaffold was embedded in
Methylmethacrylate (MMA). Fixed scaffolds were dehydrated
in a series of graded alcohols. The ethanol was cleared from
the samples by immersion in xylene (Siegfried) for 6–8 h.
Samples were embedded in MMA according to manufacturer's
instructions (Sigma-Aldrich). The samples polymerized within
5–10 days. Polymerized samples were cut with a Leica SP1600
saw microtome (Leica) to 80–100 μm thick sections, mounted
on opaque Plexiglas slides (Seamdeni) and imaged using an
Axioplan2 fluorescence microscope equipped with an
AxioCamHRc camera and AxioVision software V3.1 (Zeiss).
Statistics
Statistical analysis of data was performed using Prism
software (GraphPad). Data were tested for normal distribu-
tion and one-way ANOVA with Tukey's multiple comparison
test was applied to test for significant differences between
experimental groups. Data presented are means ± standard
error of the mean (SEM) unless stated otherwise.
Results
Abundance of CD34/CD133+ cells in human
BM aspirates
Human BM MNCs were characterized by flow cytometry.
Fig. 1(A) shows a representative forward—side scatterprofile of MNC. We focused on the region P1, containing
cells with low granularity including lymphocytes as well as
stem and progenitor cells and examined the expression of
CD34, CD133 and CD309 (Fig. 1B and Suppl. Table 1). CD34+
cells accounted for 10.9 ± 4.7% of agranular MNC. A smaller
population of CD133+ cells was detected (0.6 ± 0.5%). Of the
CD34+ cells, two distinct populations could be distinguished,
low level (CD34low) or high level (CD34high). Interestingly, all
CD133+ cells were also positive for CD34high (Fig. 1B, C), The
expression of CD309 was low (1.1 ± 1.6%, Suppl. Table 1). As
shown in Fig. 1(D, E) we could exclude a correlation between
the abundance of CD34/CD133+ cells and the age or gender
of donors.
Human BM-derived EPCCs display characteristics of
mature ECs
Following enrichment using MACS® 68.1 ± 20.7% of cells
were CD34+, 60 ± 18.5% expressed high level of CD34 and
14.3 ± 5.2% were CD34/CD133+ (Fig. 2A, B).
After monolayer expansion of EPCCs the initial expres-
sion of CD34 and CD133 was nearly completely lost (not
shown). At this stage we analyzed EPCCs with regard to
typical EC properties and compared them to HUVECs.
Firstly, we evaluated expression of CD31, expressed on
mature ECs and show that HUVECs are nearly 100%
positive for CD31, while EPCCs in passages 2 and 3 do
not express CD31 when cultured in EGM (Fig. 2C, Suppl.
Fig. 1). Secondly, we studied the ability of cells to take
up acLDL. Analysis of cell-associated fluorescence by
flow cytometry showed that both EPCCs and HUVECs
efficiently took up acLDL (Fig. 2D), with an average of
82.9 ± 12.0% and 99.5 ± 0.2% positive EPCCs and HUVECs,
respectively.
The capability of EPCCs and HUVECs to form tube-like
structures was examined on MatrigelTM. For both cell types
the formation of tube-like structures was evident after 6 h
(Fig. 2E). After 24 h, a complex network of tube-like
structures could be observed (Fig. 2E). The efficiency of
tube-like structure formation was assessed by the total tube
length after 24 h showing EPCCs are as efficient as HUVECs
(Fig. 2F). In addition, we show that EPCCs retained all
endothelial characteristics when further expanded for
another passage (Suppl. Fig. 1).
Expansion of human BM-derived EPCCs with PL
preserves endothelial characteristics
To establish an autologous culture method for EPCCs, we
used PL as a medium supplement instead of recombinant
angiogenic factors. As the composition of PL is still poorly
understood we performed a screening array to identify the
most abundant growth factors. In total, 11 out of 43 factors
were detected in PL (Fig. 3). Most abundant were the
pro-angiogenic factors RANTES (CCL5), epidermal growth
factor (EGF) and GRO (constituting CXCL1, CXCL2 and CXCL3
chemokines). Further pro-angiogenic factors including
angipoietin-1, ENA-78 (CXCL5), angiogenin, platelet-
derived growth factor BB (PDGF-BB) and transforming
growth factor beta (TGFβ) could be detected at lower
levels. Three anti-angiogenic factors were identified at low
Figure 1 Abundance of CD34/CD133+ cells in human BM aspirates. Flow cytometry analysis of mononuclear cell fractions (MNC)
obtained by density centrifugation of human BM. A. Representative profile of MNCs in respect of size (FSC) and granularity (SSC). P1
contains cells with low granularity including stem- and progenitor cells. B. Staining of CD34 (x-axis) reveals two cell population expressing
either low or high level of CD34. Staining of CD133 (y-axis) shows a small, population of CD34/CD133+ cells. C. Donor variation of CD34/
CD133+ cells. D, E. Correlation of CD34/CD133+ cells with age (D) and sex (E) of donors. n = 13. Error bars depict the SEM.
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TIMP-2 and endostatin.
Further, we studied the endothelial characteristics of
EPCCs grown in IMDM containing 2% FCS–8% PL (IMDM2-8)
or 5% FCS–5% PL (IMDM5-5). CD31 was expressed by
31.6 ± 13.85% and 41.0 ± 5.7% of cells grown in IMDM5-5
or IMDM2-8, respectively (Fig. 4A). The percentage of
CD31+ cells was higher in these media conditions when
compared to EPCCs grown in EGM (Fig. 2C). The uptake of
acLDL was significantly higher in EPCCs expanded in
IMDM2-8 than in IMDM5-5: 47.6 ± 10.8% vs. 16.5 ± 6.2%
(p b 0.05, Fig. 4B).
On MatrigelTM EPCCs grown with autologous growth
medium showed only a minor capability to form tube-like
structures (Fig. 4C). In comparison to the complex tubular
network shown by EPCCs cultured in EGM (Fig. 2), here only
short tube-like structures could be detected after 24 h of
incubation resulting in a much lower total tube length:
5.1 ± 2.0 mm were measured with IMDM5-5 and 10.5 ±
1.9 mm with IMDM2-8 (Fig. 4D), while 21.0 ± 7.6 mm could
be observed for EPCCs cultured in presence of EGM (Fig. 2F).
Comparable results were obtained for EPCCs grown for
another passage in the individual growth medium (Suppl.
Fig. 1).EPCCs promote neovascularization in vivo
To study the potential of EPCCs to trigger neovasculariza-
tion in vivo we implanted PU-HA scaffolds pre-seeded with
different proportions of MSCs and/or EPCCs in presence of
PRP subcutaneously in nude mice (Fig. 5A). Immunofluo-
rescence staining αSMA detected capillary-like structures
in all scaffolds. Fig. 5(B, C) shows representative images
of scaffolds seeded with EPCCs alone implanted directly
(Fig. 5B) or seeded with a 1:1 mixture of EPCCs and MSCs
and implanted after 1-week of pre-culture (Fig. 5C). To
address the question whether the observed vessels were
connected with the host vascular system, FITC-lectin was
intravenously injected before euthanasia of mice. FITC
staining could be detected in vessels within the implants
(Fig. 5D–F), showing that newly formed vessels were
connected to the circulation of the host mice.
Cell content, vessel number and their location were
quantified. As illustrated in Fig. 6A the sections were taken
in the center of the scaffold (dashed line, Fig. 6A(i)). We
assessed the whole cross-section of the scaffolds (Fig. 6A(ii),
plain line) as well as the center of the scaffolds (Fig. 6A(ii),
dashed line). Fig. 6(B–D) illustrates the results for directly
implanted scaffolds. Cells were detected in all cell-seeded
Figure 2 Human BM-derived EPCCs display characteristics of mature ECs. EPCCs were enriched from MNCs using CD34 and CD133 MACS®
microbeads. A. Flow cytometry analysis of the enriched cell population. Representative profile of MNC in respect of size (FSC) and granularity
(SSC). Region P1 contains cells with low granularity including stem- and progenitor cells. B. Double staining for CD34 and CD133 demonstrates
enrichment of high expressing CD34 cells and CD34/CD133+ cells. C. CD31 expression on EPCCs expanded in EGM (passage 2) and HUVECs
evaluated by flow cytometry. Only HUVECs did express CD31. D. Uptake of Dil-labeled acLDL particles, assessed by flow cytometry, was seen
in both EPCCs and HUVECs. E. Representative image of EPCCs (left panel) and HUVECs (right panel) incubated on growth factor reduced
MatrigelTM. Scale bars = 100 μm. F. Quantification of the length of tube-like structures, given values are averages obtained from analyzing
three optical fields. In all graphs single values are shown as individual dots and the mean with SEM is depicted, n = 3.
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Figure 3 Platelet-lysate as source of pro-angiogenic factors.
PL preparations from three donors were pooled and the relative
abundance of angiogenic factors was analyzed by protein
antibody array. Values are given as signal intensity in compar-
ison to an internal positive control. Bars depict mean values
with SEM, white bars show pro-angiogenic factors, black bars
indicate anti-angiogenic factors, n = 3 (referring to three
pooled samples).
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(Fig. 6B, open bars). In contrast, cell-free scaffolds showed a
lower cell content representing 1.2% and 2.3% of the total
cross sectional area. In the center of scaffolds, no variation
could be detected between the different experimental
groups with regards to cell content, range 0.6–1.5% of the
total area (Fig. 6C, open bars).
Vascular structures were identified in all experimental
groups throughout the entire scaffold (Fig. 6B, blue bars).
However, comparing vascular ingrowth into the center of
the scaffolds (Fig. 6C), the number of vessels varied
depending upon the combination of cell types seeded. In
directly implanted scaffolds the vessel number was directly
related to the number of EPCCs, although these differences
did not reach statistically significance because of huge
variations between individual scaffolds (Fig. 6C, blue bars).
We also analyzed the penetration depth of individual vessels
into the scaffolds. Compared to cell-free PU-HA scaffolds
(140 ± 16 μm) a significant higher mean penetration was
observed with 100% EPCC (216 ± 10 μm, p b 0.01) and with
75% EPCC + 25% MSC (203 ± 12 μm, p b 0.05, Fig. 6D).
Overall, pre-cultured scaffolds showed a slightly lower
cell content than directly implanted scaffolds, ranging
between 1.6% and 2.3% of the total area (Fig. 7A, open
bars). Similar numbers were detected in the center of
scaffolds (Fig. 7B, open bars). The highest vessel number
was detected in the center of scaffolds containing
co-cultures of EPCCs and MSCs (Fig. 7B, blue bars): 2.4 ±
0.4 vessels in scaffolds seeded with 50% EPCC + 50% MSC
(p b 0.05 in comparison to monocultures: 100% EPCC: 0.8 ±
0.2; 100% MSC 0.7 ± 0.3). The positive influence of MSC–
EPCC co-cultures was also confirmed when we analyzed the
penetration depth of vascular structures into the scaffolds
(Fig. 7C). A significantly higher mean depth of 266 ± 15 μmwas detected in scaffolds co-seeded with 50% MSC + 50%
EPCC in comparison to 171 ± 11 μm for 100% MSC (p b 0.001)
and 211 ± 10 μm for 100% EPCC (p b 0.05), which was also
higher compared to directly implanted scaffolds (Fig. 6D).Discussion
Human BM-derived EPCCs display similar angiogenic
properties to HUVECs
In this study we demonstrate that BM-derived EPCCs
promote neovascularization in tissue-engineered scaffolds.
We show the abundance of a distinct population of CD34/
CD133+ cells in human BM aspirate in all tested donors
independent of age or gender. These cells contain a
hematopoietic progenitor cell population bearing the po-
tential to develop an EC phenotype when cultured in the
presence of angiogenic growth factors (Peichev et al., 2000;
Gehling et al., 2000; Quirici et al., 2001). Accordingly,
various transplantation strategies to treat ischemic diseases
have been focused on CD34+ cells (Kuroda et al., 2014).
Interestingly, extensive work on circulating blood EPCs has
revealed that the CD34+ CD133+ VEGFR2+ cell population
failed to give rise to an EC population but formed
hematopoietic colonies (Case et al., 2007). Work from the
same group identified CD34+/CD45− cells as a putative EPC
population and further studies showed that the cells express
a combination of the EC marker CD34, CD31 and CD146 while
CD133 and CD45 were absent (Case et al., 2007; Mund et al.,
2012).
In the current study we enriched CD34/CD133+ cells using
the MACS® microbeads system. Although the obtained cell
population was not pure, MACS® enrichment presents a fast
selection strategy requiring only minimal manipulation of
cells which is of particular interest for clinical application.
From a clinical point of view it is thought advantageous to
work with a mixture of progenitor cells. Recent work has
suggested that monocytic cells might also promote neovas-
cularization (Shi et al., 2014).
We show that after an expansion EPCCs for two passages
(~3 weeks) in angiogenic growth medium, cells had EC
characteristics.
During the past years, many approaches have used various
EPC populations to induce neovascularization in tissue-
engineered scaffolds (Critser et al., 2011; Zisch, 2004;
Johnson et al., 2011). EPCs have also been applied in the
treatment of ischemic diseases (Krenning et al., 2009; Drela
et al., 2012; Zhao et al., 2013). However, in the majority of
these studies EPCs were derived from blood or even mature
ECs were used. Such strategies require a time-consuming
and expensive in vitro expansion because of a generally low
yield of cells and/or limited proliferation potential. Blood
outgrowth ECs appear as cobblestone-like cell colonies
4 weeks after cell isolation and then require further in
vitro expansion (Kolbe et al., 2010). In contrast, we show
that BM-derived EPCCs require a much shorter time of in
vitro manipulation, namely colonies were present within a
week after isolation. The superior proliferation potential of
EPCCs from BM in comparison to blood-derived EPCs has also
been reported by others (Muscari et al., 2010).
Figure 4 Expansion of human BM EPCCs with PL preserves endothelial characteristics. BM-derived EPCCs (passage 2) expanded in
IMDM supplemented with autologous growth factors: IMDM with 5% FCS–5% PL (IMDM5-5) or 2% FCS–8% PL (IMDM2-8). A. Expression of
CD31 evaluated by flow cytometry. B. Uptake of Dil-labeled acetylated LDL particles analyzed with FACS. C. Tube-like structure
formation capability on MatrigelTM. Scale bars = 100 μm. D. Quantification of total tube length, given values are average values
obtained from analyzing three optical fields each. In all graphs single values are shown as individual dots and the mean with SEM is
depicted, n = 3, *p b 0.05.
472 M. Herrmann et al.To assess the potential of human BM-derived EPCCs to
function as mature ECs we first cultured these cells in EGM
medium. Our results confirmed that EPCCs cultured in EGM
have the same functional properties as mature HUVECs,
demonstrated by their ability to take up acLDL and form
tube-like structures on MatrigelTM. In contrast, some recent
in vitro studies have shown a limited endothelial potential of
BM-derived EPCs. Amini et al. found that rabbit peripheral
blood EPCs showed a higher expression of EC markers and a
more pronounced ability to form tubular structures in
MatrigelTM in vitro than BM-derived EPCs (Amini et al.,
2012). Similarly, Chen et al. reported that mouse BM-derived
EPCs failed to sprout in an in vitro 3D sprouting model (Chen
et al., 2012). The different outcomes of these studies may
be attributed to the fact that phenotypic characterization of
EPCs depends on various factors including species, cell
source and culture conditions (Timmermans et al., 2009).
Studies analyzing EPCs of various species have shown that
the selection and culture conditions may significantly impact
proliferation, differentiation and maturation of these cells.Jianguo et al. reported that a combination of VEGF, bFGF,
IGF and EGF was required for an optimized culture of porcine
EPCs (Jianguo et al., 2010). Another study using porcine EPCs
identified fibronectin-coating and VEGF as crucial factors to
promote the endothelial properties of EPCs (Muscari et al.,
2010). Interestingly, our data suggest that EPCCs cultured in
EGM do not express CD31. Similar observations were made
for in vitro amplified BM-derived EPCs from different species
including rat, mouse and rabbit (Amini et al., 2012; Yang et
al., 2011; Sekiguchi et al., 2011). However, the lack of CD31
expression at this point may be attributed to the in vitro
monolayer culture and has no influence on the functional
properties of EPCCs, demonstrated by the ability of EPCCs to
form tube-like structures on MatrigelTM.
In accordance with other studies, our data show that
BM-derived EPCCs are highly efficient in promoting neovas-
cularization in vivo. Similarly, Yu et al. demonstrated the
potential of mouse BM-derived EPCs co-seeded with osteo-
blasts in a porous scaffold to induce capillarization in a
segmental bone defect model (Yu et al., 2009). Another study
Figure 5 Neovascularization and anastomosis of vessels in subcutaneously implanted PU-HA scaffolds. A. PU-HA scaffolds were
seeded with different proportions of EPCCs and MSCs in presence of PRP (n = 5). Empty scaffolds or scaffolds with PRP alone served as
control (n = 2). Scaffolds were implanted subcutaneously into nude mice for 8 weeks. B–D. αSMA immunofluorescence staining (red)
on cryosections detecting micro-vessels. Cell nuclei are stained with DAPI (blue). D-F. Detection of intravenously injected FITC-lectin
(green) within micro-vessels on cryosections (D, green, arrowheads; asterisks = autofluorescence of the scaffold) and MMA-sections
(E, F). Shown are representative images of a directly implanted scaffold seeded with 100% EPCCs (B, D) or 25% MSC + 75% EPCC (E.).
C and F show images of scaffolds seeded with 50% MSC + 50% EPCC (C) or 25% MSC + 75% EPCC (F) and implanted after 7 days in vitro
pre-culture. Scale bars depict 200 μm (B, C), 100 μm (F), 50 μm (D, E).
473CD34/CD133 enriched bone marrow cells promote neovascularization of constructsdemonstrated the successful vascularization of MSC seeded
porous β-tricalcium phosphate ceramic scaffolds in rabbits
when BM-derived EPCs were added (Zhou et al., 2010). Zhang
et al. observed that rabbit BM-derived EPCs were capable to
generate a vascular network in osteogenic cell sheets (Zhang
et al., 2012). Recently, Pang et al. showed that the addition
of rabbit BM-derived EPCs to a demineralized bone matrix
seeded with MSCs improved vascularization and healing of the
defect in vivo (Pang et al., 2013).Culture of EPCCs with autologous platelet-derived
growth factors
We have previously reported that PL, containing autologous
growth factors, boosts the expansion of EPCs in vitro
(Lippross et al., 2011). In particular, the proliferation of
EPCs was optimal in a medium containing 5% FCS and 5% PL.
In addition, EPCs cultured with PL expressed endothelial
markers such as angiopoitin 1, von Willebrand Factor (vWF),
Figure 6 EPCCs promote neovascularization in directly im-
planted scaffolds in vivo. Quantitative analysis of vessel number
and cell content in entire scaffolds (B) and in the center of
scaffolds (C) as indicated in (A). Immunofluorescence staining
for αSMA was performed as shown in Fig. 5 to detect blood
vessels in directly implanted scaffolds. The cell content was
estimated by measuring the area covered by DAPI nuclei
staining. D. Depiction of the penetration depth of vessels,
each dot corresponds to one vessel. N.B. the number of vessels
in scaffold center was the highest in scaffolds with 100% EPCC.
Bars depict mean values with SEM, n = 5 (cell-seeded scaffolds),
n = 2 (cell-free scaffolds), *p b 0.05, **p b 0.01.
Figure 7 EPCC–MSC crosstalk is crucial for neovascularization
in pre-cultured scaffolds.
Quantitative analysis of vessel number and cell content in entire
scaffolds (A) and in the center of scaffolds (B). Immunofluores-
cence staining for αSMA was performed as shown in Fig. 5 to
detect blood vessels in pre-cultured scaffolds. The cell content
was estimated by measuring the area covered by DAPI nuclei
staining. C. Depiction of the penetration depth of vessels, each
dot corresponds to one vessel. N.B. the number of vessels in
scaffold center was the highest in scaffolds with 50% MSC + 50%
EPCC. Bars depict mean values with SEM, n = 5, *p b 0.05,
***p b 0.001.
474 M. Herrmann et al.PDGF-RB, TEK tyrosine kinase and CD31 and were able to
build tube-like structures on Matrigel™, which was never
observed with FBS alone (Lippross et al., 2011). This is in
agreement with earlier studies having shown that platelets
induce the differentiation of EPCs (Langer et al., 2007) and
promote colony formation as well as migration of EPCs
(Leshem-Lev et al., 2010).
To better understand the effect of PL on EPCCs, we
analyzed PL with respect to its content of angiogenic
factors. We found high levels of the pro-angiogenic factors
RANTES, EGF and GRO (Suffee et al., 2012; Arenberg et al.,
1997). A comparable profile was described by Fekete et al.
reporting the expression of high levels of RANTES along withother pro-angiogenic factors including PDGF-AA, PDGF-AB/
BB and TGFβ in human PL. This study also revealed the
presence of GRO and bFGF (Fekete et al., 2012). In the
current study we detected PDGF-BB and TGFβ only at minor
levels, which might be attributed to the different activation
method of the platelets or donor variability. Indeed high
variation in growth factor content of different platelet
preparations has been reported before (Lubkowska et al.,
2012). In our study we could not detect VEGF, one of the
most prominent pro-angiogenic growth factors. This corre-
sponds with our previous study, where the VEGF concentration
475CD34/CD133 enriched bone marrow cells promote neovascularization of constructsin PL was determined as 5 ng/ml using ELISA (Duttenhoefer et
al., 2013), which may be below the detection level of the
membrane-based assay used in the current study. Low
expression levels of VEGF as well as donor variability have
also been shown by others (Lubkowska et al., 2012).
Interestingly, certain anti-angiogenic factors, including
Timp-1, Timp-2 and endostatin were detected in our PL
preparations, although at low levels.
We tested two different PL-containing culture media and
directly compared them to EGM containing recombinant
growth factors. Considering the functional properties of
EPCCs, specifically the uptake of acLDL and tube formation
on Matrigel™, EGM showed better results than either
PL-containing media. This might be explained by the
absence of prominent pro-angiogenic factors such as VEGF
as well as the presence of anti-angiogenic factors in PL as
discussed above. Thus, we suggest that expansion of EPCCs
in the PL-containing medium retains EPCCs in a more
immature, progenitor-like state. Nevertheless, our animal
study clearly demonstrated that EPCCs grown in PL-containing
medium were able to promote the formation of functional
capillary-like structures in vivo.EPCC–MSC crosstalk is crucial for neovascularization
In our in vivo study, we observed significantly more vessel
formation in pre-cultured scaffolds seeded with MSCs and
EPCCs in comparison to monocultures. Along with our earlier
work, this indicates that interactions of MSCs and EPCCs are
required to promote neovascularization. In an earlier study,
we studied similar co-cultures in vitro and found a more
pronounced tube formation in MSC–EPC co-cultures com-
pared to single cultures (Duttenhoefer et al., 2013). We
demonstrated the presence of pericytic cells, which have a
stabilizing effect on the newly formed vessels. Recent work
from our group further showed that a pericyte-like pheno-
type is induced in MSC–EPCC co-cultures after 3 days and
that MSCs are the origin of pericytic cells (Loibl et al., 2014).
A direct cell-to-cell contact was crucial to promote the
differentiation of MSCs. Similar results were reported by
Goerke et al. suggesting that the formation and stabilization
of vessels is supported by MSCs, which in presence of EPCs,
differentiate towards smooth muscle cells (Goerke et al.,
2012). Another study demonstrated a cross-talk between
MSCs and EPCs evoking an upregulation of pro-angiogenic
factors (Aguirre et al., 2010). This was attributed to both, a
direct cell-to-cell contact and paracrine signaling. It has
been shown that paracrine signaling involves BMP-2, which in
turn upregulates the expression and secretion of angiogenic
factors in EPCs (Raida et al., 2006; Nukavarapu and Amini,
2011; Song et al., 2011). The efficient neovascularization
that was detected in scaffolds with MSC–EPCC co-cultures
might thus be facilitated by both, the formation of
stabilizing pericytic cells and by pro-angiogenic factors.
Several recent in vivo studies confirmed that MSC–EPC
interactions facilitate the vessel-formation abilities of EPCs.
Fedorovitch et al. showed that addition of MSCs supported
the tube formation by blood-derived EPCs in a MatrigelTM
plaque assay in vivo (Fedorovich et al., 2010). Moreover,
co-cultures of MSCs with either blood- or BM-derived EPCs
have been shown to promote neovascularization in variousbone tissue engineered constructs in vivo (Fuchs et al.,
2009; Henrich et al., 2009; Pang et al., 2013; Zhang et al.,
2012; Seebach et al., 2012). Interestingly in the current
study, the beneficial effects of MSC–EPCC co-cultures were
only detected in pre-cultured scaffolds. Nevertheless, we
could detect vascularization in the center of directly
implanted scaffolds. Here, we suggest that the mechanism
of neovascularization may be different. In pre-cultured
scaffolds the period of in vitro culture allows the formation
of early tubular structures prior implantation, as previous
work has shown (Duttenhoefer et al., 2013). In contrast, in
directly implanted scaffolds cells are challenged to the in
vivo situation in an undifferentiated state. Given the
considerable size of scaffolds and the consequent limitations
of diffusion of oxygen and nutrients into the scaffold
(Folkman and Hochberg, 1973; Auger et al., 2013) it is
reasonable to assume that MSCs may not survive in this
setting. Additionally, it has been shown that EPCs may
adjust to hypoxic conditions (Hoffmann et al., 2013).
Further, EPCs may act as a source of chemoattractant
factors (Krenning et al., 2009). Taken together this might
explain the positive relationship between the number of
EPCCs and the number of detected vessels in directly
implanted scaffolds.Conclusions
In conclusion, the current study identifies BM-derived EPCCs
as an autologous source of cells with high angiogenic
potential. Furthermore, EPCCs preserve their endothelial
potential when cultured with platelet-derived autologous
growth factors in vitro and in vivo. Thus, BM-derived EPCCs
are a promising source of cells to promote neovasculariza-
tion in tissue engineered constructs.Acknowledgments
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